Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q3 2024 · 10-Q
Revenue$7.55B$7.55B+7.0% vs Q3 2023 Net Income$1.25B$1.25B−42.5% vs Q3 2023 EPS Diluted$1.00$1.00−42.2% vs Q3 2023 Operating Income$888,000,000−66.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$4,168,000,000+155.2% Margins · derivedOperating margin11.8%−25.4 pt vs Q3 2023
Net margin16.6%−14.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end